The stock of Harmony Biosciences Holdings Inc (HRMY) has seen a -4.85% decrease in the past week, with a -3.03% drop in the past month, and a 1.86% flourish in the past quarter. The volatility ratio for the week is 2.76%, and the volatility levels for the past 30 days are at 2.05% for HRMY. The simple moving average for the past 20 days is -4.24% for HRMY’s stock, with a -3.78% simple moving average for the past 200 days.
Is It Worth Investing in Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Right Now?
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has a higher price-to-earnings ratio of 12.71x compared to its average ratio, The 36-month beta value for HRMY is at 0.87. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HRMY is 43.61M, and currently, shorts hold a 7.75% of that float. The average trading volume for HRMY on June 13, 2025 was 702.87K shares.
HRMY) stock’s latest price update
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has seen a decline in its stock price by -5.15 in relation to its previous close of 35.14. However, the company has experienced a -4.85% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-06-11 that PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. The data will be presented at the 39th Annual Meeting of the Associated Professi.
Analysts’ Opinion of HRMY
Many brokerage firms have already submitted their reports for HRMY stocks, with Oppenheimer repeating the rating for HRMY by listing it as a “Outperform.” The predicted price for HRMY in the upcoming period, according to Oppenheimer is $61 based on the research report published on June 02, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see HRMY reach a price target of $55. The rating they have provided for HRMY stocks is “Buy” according to the report published on February 11th, 2025.
H.C. Wainwright gave a rating of “Buy” to HRMY, setting the target price at $75 in the report published on December 17th of the previous year.
HRMY Trading at 3.61% from the 50-Day Moving Average
After a stumble in the market that brought HRMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.90% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HRMY starting from JEFFREY G DIERKS, who proposed sale 5,615 shares at the price of $35.98 back on Jun 10 ’25. After this action, JEFFREY G DIERKS now owns shares of Harmony Biosciences Holdings Inc, valued at $202,009 using the latest closing price.
JEFFREY G DIERKS, the Former Officer of Harmony Biosciences Holdings Inc, proposed sale 9,844 shares at $35.56 during a trade that took place back on May 19 ’25, which means that JEFFREY G DIERKS is holding shares at $350,083 based on the most recent closing price.
Stock Fundamentals for HRMY
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.78 for the gross margin
The net margin for Harmony Biosciences Holdings Inc stands at 0.21. The total capital return value is set at 0.22. Equity return is now at value 24.71, with 16.05 for asset returns.
Based on Harmony Biosciences Holdings Inc (HRMY), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 12.72. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 21.37.
Currently, EBITDA for the company is 233.41 million with net debt to EBITDA at -2.12. When we switch over and look at the enterprise to sales, we see a ratio of 1.94. The receivables turnover for the company is 7.03for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.67.
Conclusion
In conclusion, Harmony Biosciences Holdings Inc (HRMY) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
